[Adverse events of ABL tyrosine kinase inhibitors in chronic myeloid leukemia therapy]

Tetsuzo Tauchi

doi:10.11406/rinketsu.59.2089

[Adverse events of ABL tyrosine kinase inhibitors in chronic myeloid leukemia therapy]

Rinsho Ketsueki. 2018;59(10):2089-2093. doi: 10.11406/rinketsu.59.2089.

[Article in Japanese]

Author

Tetsuzo Tauchi¹

Affiliation

¹ Department of Hematology, Tokyo Medical University.

PMID: 30305513
DOI: 10.11406/rinketsu.59.2089

Abstract

Fatal events during treatment with ABL tyrosine kinase inhibitors (ABL TKIs) have been reported, and there have been concerns of high mortality rate in patients with chronic myeloid leukemia receiving ABL TKIs. The predictive factors of patients treated with ABL TKIs who are at risk of potentially fatal toxicities remain unknown. Although this scenario appears discouraging, the risk of severe toxicity might be predicted by investigating the effect of genetic variation on the disposition of ABL TKIs. Global genomic surveys should be conducted to identify factors contributing to an increased risk of toxicity using multivariable analyses with particular reference to ABL TKIs pharmacokinetics and baseline clinical characteristics.

Keywords: ABL kinase inhibitor; Adverse events; BCR-ABL1.

Publication types

Review

MeSH terms

DNA Mutational Analysis
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Protein Kinase Inhibitors / toxicity*

Substances

Protein Kinase Inhibitors